LUng MRI for Risk Stratification to select NSCLC treatment - LUMRIS
Research type
Research Study
Full title
LUng MRI for RIsk Stratification to select non-small cell lung cancer patients for radical treatment (LUMRIS)
IRAS ID
274155
Contact name
Matthew Hatton
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Lung cancer is the most common cancer in Yorkshire with over 4,500 new cases diagnosed each year and survival rates remain very disappointing with less than 10% of patients still alive 5 years after their diagnosis. Radiotherapy and surgery are the cornerstones of potentially curative treatment but both run the risk of serious complications, especially in patients with poor lung function. Sadly, the most lung cancer patients in Yorkshire have other lung diseases reducing their lung function increasing the risk of radiotherapy or surgery.
Selecting the best treatment for individual patients, surgery or radiotherapy, is a complex process requiring comprehensive and accurate assessment of lung function. Currently, these decisions are made using relatively simple lung function tests that only provide whole-lung measures which often poorly predict lung function following treatment.
More accurate lung function tests would help doctors and this study investigates if a cutting-edge functional lung MRI scan, developed and used in Sheffield, can give extra information that can help identify the patients most likely to benefit from radiotherapy and surgery and enable doctors to offer these treatments to a wider range of patients.
This study assesses the feasibility of introducing functional lung MRI into the current lung cancer diagnostic pathways across a cancer network and will look at its potential impact on decision making.
40 patients from South Yorkshire (Sheffield and Doncaster) being considered for curative surgery or radiotherapy will be recruited to this study. Patients will undergo lung function tests and imaging at 3 timepoints: prior to treatment, 3 and 12 months post-treatment.
This study has the potential to directly benefit lung cancer patients improving selection for treatment and contribute to our understanding of lung function when selecting patients for potentially curative treatment options.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
20/YH/0069
Date of REC Opinion
9 Mar 2020
REC opinion
Favourable Opinion